Madrid, SpainSpotlight on rivoceranib
Come see the TKI selectivity comparison, the latest rivoceranib data, information on our pipeline, and more.
Learn how the mechanism of action of rivoceranib helps define its clinical potential.
Immersive experience
See the relative selectivity of TKIs through our interactive touchscreen display.
Review our latest data
Visit the poster presentation
Sunday, October 22 | 12:00-13:00 | Hall 8 644P
Abstract Title: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib plus Trifluridine/Tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer
See the phase 3 study results published in The Lancet
At ESMO 2022, we presented our proffered paper on the phase 3 study results comparing rivoceranib in combination with camrelizumab vs sorafenib as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). Look how far we’ve come!
See the phase 3 study results published recently in The Lancet showing a statistically significant and clinically meaningful benefit in progression-free survival and overall survival.
Explore the Past. Experience the Present. Map the Future.
Explore the Past.
Experience the Present.
Map the Future.
Enjoy and explore
Stop by booth 726a for a latte and explore the past, present, and future of treatment for unresectable hepatocellular carcinoma (uHCC).
Stay connected
Sign up to receive important information about rivoceranib, company news and updates, or to connect with a member of our team.
